Hansoh Pharmaceutical (03692.HK) Rises Over 3% as Aumolertinib Gains Rapid Market Traction Post-Launch with Broad Growth Potential

According to the Zhitong Finance APP, Hansoh Pharma (03692) rose over 3%. As of the time of writing, it was up 3.25%, trading at HK$19.08, with a turnover of HK$57.6911 million.

On the news front, on July 19, the marketing application for the first domestically developed third-generation EGFR-targeted drug in China, Hansoh Pharma's Almonertinib for adjuvant treatment of postoperative lung cancer, was accepted by the National Medical Products Administration (NMPA), drawing significant attention from the industry. According to China Investment Consulting, with the advantages of being a first mover and supported by national medical insurance, Almonertinib quickly gained market share after its launch, consistently holding the largest market share among domestically produced third-generation EGFR-targeted drugs in China. However, with the continuous expansion of domestically produced third-generation EGFR-targeted drugs and the high overlap of indications among various products, Almonertinib is opening up new battlegrounds, which will secure broader market growth opportunities.

CICC released a research report stating that after three years of systematic adjustments, the pharmaceuticals sector has entered a value investment range. With domestic policies gradually stabilizing and relevant policies for innovative drugs being introduced in China, the domestic innovative drug industry chain and overseas expansion are worth watching in the second half of 2024. The bank believes that under the new normal in the second half of the year, the resumption of bidding is expected to gradually release demand that was suppressed over the past year. The unclear outlook for global economic growth makes cost-effective Chinese manufacturing more attractive. This translates to an increase in localization rates in the domestic market and accelerated exports abroad.